{
    "clinical_study": {
        "@rank": "3028", 
        "arm_group": {
            "arm_group_label": "Icotinib", 
            "arm_group_type": "Experimental", 
            "description": "Icotinib will be administered 250 mg one time by month, 3 times per day."
        }, 
        "brief_summary": {
            "textblock": "To evaluate the efficacy and safety of increased dose of icotinib in advanced NSCLC patients\n      who progressed after gefitinib therapy."
        }, 
        "brief_title": "Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Non-small Cell Lung Cancer", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Small Cell Lung Carcinoma"
            ]
        }, 
        "detailed_description": {
            "textblock": "This single center, single arm open label study is designed to assess the safety and\n      efficacy of using high dose of Icotinib (Conmana) as a way to treat patients with non-small\n      cell lung cancer that progressed after routine gefitinib therapy by progression-free\n      survival, as well as overall survival and disease control rate. The adverse events and\n      adverse reaction are evaluated as well."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed local advanced or metastatic stage IIIB/IV\n             NSCLC.\n\n          -  Have been treated with gefitinib and achieved completed response, partial remission,\n             or stable disease within 3 months after first dose of gefitinib.\n\n          -  At least one measurable lesion according to Response Evaluation Criteria in Solid\n             Tumors.\n\n          -  Signed and dated informed consent before the start of specific protocol procedures.\n\n        Exclusion Criteria:\n\n          -  Allergic to icotinib.\n\n          -  Gefitinib excepted, experience of Anti-tumor Monoclonal Antibody or small molecular\n             compounds therapy  such as erlotinib or Cetuximab.\n\n          -  Severe systemic disease out of control such as unstable or uncompensated\n             respiratory,cardiac,liver,renal diseases."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 31, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01720901", 
            "org_study_id": "BD-IC-IV41"
        }, 
        "intervention": {
            "arm_group_label": "Icotinib", 
            "description": "Icotinib will be administered 250 mg one time by month, 3 times per day.", 
            "intervention_name": "Icotinib", 
            "intervention_type": "Drug", 
            "other_name": [
                "Conmana", 
                "BPI-2009"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": "Gefitinib"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Changsha", 
                    "country": "China", 
                    "state": "Hunan", 
                    "zip": "410008"
                }, 
                "name": "Xiangya Hospital, Central-South Univercity"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open, Single-Center,Single Arm Trial to Evaluate the Efficacy and Safety of Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy", 
        "overall_official": {
            "affiliation": "Xiangya Hospital, Central-South Univercity", 
            "last_name": "Hu Chengping, M.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Progression-free survival is defined as a duration from the date that first dose is given to disease progression or death.", 
            "measure": "Progression-free survival", 
            "safety_issue": "No", 
            "time_frame": "4.5 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01720901"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Overall survival is a duration from the date that first dose is given to the date of death.", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "Tumor response is designed by imaging according to Response Evaluation Criteria in Solid Tumors, including complete response, partial remission, stable disease as well as progressed disease.", 
                "measure": "Tumor response", 
                "safety_issue": "No", 
                "time_frame": "6 weeks"
            }, 
            {
                "description": "Adverse events will be coded in term of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events.", 
                "measure": "Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Betta Pharmaceuticals Co.,Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Betta Pharmaceuticals Co.,Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}